S&P Futures
4,217.50+3.75(+0.09%)Dow Futures
33,794.00+33.00(+0.10%)Nasdaq Futures
14,134.25+4.25(+0.03%)
LivaNova PLC (LIVN)
After hours: 04:46PM EDT
Chart Events
Performance Outlook
| Previous Close | 82.25 |
| Open | 82.65 |
| Bid | 84.12 x 800 |
| Ask | 84.22 x 800 |
| Day's Range | 81.79 - 84.48 |
| 52 Week Range | 41.07 - 90.25 |
| Volume | 235,933 |
| Avg. Volume | 317,790 |
| Market Cap | 4.107B |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.47 |
| Earnings Date | Jul 27, 2021 - Aug 02, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 95.17 |
- Business Wire
LivaNova Receives FDA Approval for Clinical Study to Evaluate the aura6000 System to Treat Obstructive Sleep Apnea
LONDON, Jun 15, 2021--LivaNova PLC announced it received approval from the U.S. FDA to proceed with its IDE clinical study, OSPREY, for obstructive sleep apnea treatment.
- GlobeNewswire
Helius Medical Technologies, Inc. Appoints Frederick Fantazzia as Vice President of Sales & Marketing, North America
NEWTOWN, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the appointment of Frederick Fantazzia to the position of Vice President of Sales & Marketing, North America, effective June 1, 2021. “Fred is a dynamic leader with 16 years of sales and marketing experience in the field of neuromodulation, and a specific focus on developing the market for new
- Business Wire
LivaNova Completes Initial Closing of Heart Valve Business to Gyrus Capital
LivaNova PLC today announced it has successfully completed the initial closing of the divestiture of its heart valve business to Gyrus Capital.
